Telix Pharmaceuticals and RefleXion Medical Enter Strategic Collaboration for Treatment of High-Risk Cancers
Melbourne (Australia) – 8th July 2020. Telix Pharmaceuticals Limited announces it has entered into a strategic collaboration agreement with RefleXion Medical
Telix Pharmaceuticals Limited is delighted to announce it has entered into a strategic collaboration agreement with Hayward, USA based RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy1 (BgRT) as a new modality for treating all stages of cancer, to investigate the clinical utility of combining the companies’ technologies to improve treatment for high-risk or recurrent prostate and aggressive kidney cancers.
To read the full media release please click here.